The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...

CDMO ProBio, the biologics subsidiary of GenScript, expanded its plasmid DNA and viral vector production capacity with the opening of new manufacturing facility in Hopewell, New Jersey. The site, ...

Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production Asimov’s LV Edge Packaging cell line routinely achieves high ...